Work Group Recap 1 of 12 November 2021

November 2021 Virtual Interim Work Group Recaps:

For results of Data Element Request Forms (DERFs) and External Code List (ECLs) reviewed see DERF Resolution at [https://member.ncpdp.org/work-groups.aspx?ID=wgmc](https://member.ncpdp.org/work-groups.aspx?ID=wgmc).

**Work Group 1 Telecommunication**

Ballot Adjudicated:

- **Ballot WG010087** – Enhancements to the Telecommunication Standard Implementation Guide Version F8 and Post Adjudication Standard Implementation Guide Version 53 is considered a valid ballot having received 60+% of Consensus Group votes and 75+% approval rating. One affirmative with comment was received. WG1 reviewed and categorized the comment as not persuasive. See Letter Ballot Comment spreadsheet for the ballot results and categorization of comments on the WG1 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:

- DERF 001835 was approved as modified.
- DERF 001854 was approved.
- DERF 001855/ECL 000355 was recommended to MC to approve.
- DERF 001856/ECL 000356 was recommended to MC to approve as modified.
- DERF 001857/ECL 000357 was recommended to MC to approve.
- DERF 001858/ECL 000358 was recommended to MC to approve as modified.
- DERF 001859/ECL 000359 was recommended to MC to approve as modified.

Task Groups:

- The **Telecommunication FAQ Task Group** reviewed five DERFs, one FAQ from the WG1 Coordination of Benefits (COB) Task Group and two FAQs from MC Definition and Use of Quantity and Day Supply Task Group. The task group also formed the Prior Authorization Transaction Consolidation Review Sub-Task Group to evaluate current and future use of the Telecommunication P1 – P4 Prior Authorization transactions and disbanded the FAQ Controlled Substance Guidance Update Sub-Task Group. The task group approved publication of an FAQ regarding mixed capitalization.
  - The **FAQ Controlled Substance Guidance Update Sub-Task Group** disbanded with approval from the parent task group because their goal was completed.
  - The **Prior Authorization Transaction Consolidation Review Sub-Task Group** created an industry survey to determine if the Telecommunication P1 – P4 transactions are being used.

- The **P and C/WC Monitoring, Billing and Education Task Group** presented legislative and regulatory developments from the last quarter.

- The **Coordination of Benefits (COB) Task Group** reviewed the Payer Sheet Template and provided recommendations to the SNIP Committee around a single COB method per unique BIN/PCN. The task group reviewed COB FAQ #92 regarding the use of tax fields, reviewed an FAQ submitted by WG9 Medicare Part D Task Group, answered a question received explaining Other Coverage Code values, COB methods and what fields to use based on the COB method and previous payer
response. The task group also provided guidance to WG9 Government Programs Encounter Reporting Standard Task Group on the COB section of the Medicaid Pharmacy Encounters Reporting Standard Implementation Guide. A letter to be sent to Medicare offices and state Medicaid agencies regarding the publication of the Dual Eligible Part B Claims Processing Barriers and Recommendations White Paper was drafted and is undergoing final revisions.

- The **Information Reporting Problems Task Group** completed their review of assigned Chapter 14 sections, is updating *NCPDP Guidance for SPAPs and ADAPs Medicare Part D Coordination of Benefits Requirements and Responsibilities* and reviewed the HPMS memo dated September 9, 2021, stating CMS updated the HPMS SPAP/ADAP module to include two contact information fields: Contact Information for CMS and Contact Information for Beneficiary Inquiries.

- The **Post Adjudication Task Group** did not meet this quarter.

- The **Definition of a Valid Prescriber Task Group** discussed the September preclusion file coming out with a deleted record. They will continue to monitor this. The task group is working on updates to the provider information in the *Telecommunication Version D and Above Questions, Answers and Editorial Updates*.

- The **Eligibility Verification Enhancements Task Group** did not meet this quarter.

- The **Benefit Integration Task Group** reviewed new fields needed for benefit synchronization. They began final review of all related documents corresponding with the changes made for benefit synchronization.

- The **Standardized Subrogation Task Group** did not meet this quarter.

- The **Expand Dollar Fields Task Group** did not meet this quarter.

- The **Clinical and Safety Edits Task Group** began reviewing opioid overrides for items such as sickle cell disease and discussed possible needs for changes to the published opioid one-pager, but that work was put on hold until the task group can complete a review of the DUR Codes which is currently in progress.

- The **Point of Sale Rebate Review Task Group** reviewed Virginia H 2007 and West Virginia H 2263 bills at a task group member’s request and determined they were not relevant to NCPDP standards. The task group will go on hiatus until further action from the government regarding point of sale rebates.

- The **Telecommunication Agility Next Generation (TANG) Task Group** presented a recommendation for the Telecommunication Standard transition to JSON and conducted a straw poll that indicated option B of the presentation is the preferred transition plan. They continue to develop a high-level road map that transitions the Claim Billing and Eligibility transactions towards JSON.

- The **Pharmacy Product Locator Task Group** performed outreach to encourage additional participation and built a swim lane workflow of the pharmacy to pharmacy product location tool.

- The **Pharmacy Services Billing Task Group** streamlined the task group focus to use case development, is summarizing S1 to 837P technical gaps and opportunities, is drafting a white paper to educate and communicate the benefits of the S1 transaction within the pharmacy industry and is creating FAQ guidance to address identified gaps. The task group drafted a use case template and will be coordinating with the Pharmacy HIT Collaborative.

Other Reportables:

• **MC REMS Workflow to Transaction Task Group, MC RTPB Standard Task Group and MC SNIP Task Group:** Recaps for these task groups were provided in the WG1 download materials.

New Business:
• Two straw polls were conducted to determine the use of rebill transactions today.

**Work Group 2 Product Identification**

Ballot Adjudicated:
• **Ballot WG020012** Enhancements to the Product Identifiers Standards Implementation Guide Version 1.6 is considered a valid ballot having received the required 60+% of Consensus Group votes and 75+% approval rating. One affirmative with comment was received. WG2 reviewed and categorized the comment as persuasive and editorial. See Letter Ballot Comment spreadsheet for the ballot results and categorization of comments on the WG2 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs Reviewed:
• DERF 001860 was approved.

Old Business:
• Tammy Powell of the National Library of Medicine (NLM) provided an update on RxNorm and DailyMed.

Task Groups:
• The **Product Review and Billing Unit Exception Task Group** reviewed issues resulting from changes to existing products or to the release of new products. The task group:
  o Reviewed and submitted to WG2 for adjudication one new QUIC form (see final adjudication determination by the Work Group in this report):
    ▪ QUIC #202103 Enzyvant Rethymic®
  o Reviewed two products via email and one during task group calls for verification of the package size or billing unit to list within the drug data compendia files.
  o Completed and submitted DERF 001860 to update to FAQ 7.39: How are radiopharmaceuticals to be billed? in the *NCPDP Billing Unit Standard Implementation Guide*. The current process outlined in the FAQ was found to be incomplete and inaccurate due to the unique nature of radiopharmaceuticals decaying over time. In addition, their pricing is often related to billing units not supported by the Billing Unit Standard, such as the radioactive units of MBQ (megabecquerel), MCi (millicuries) or Ci (curies) causing confusion as to how radiopharmaceuticals should be billed.
  o At the invitation of the FDA, WG2 leadership and a select group of task group members participated in an FDA listening session on 08/09/2021 to discuss NCPDP’s perspective regarding the time needed to transition to use of the Unique Device Identifier (UDI). The FDA is considering the possibility of holding a broad stakeholder meeting in the future to address the industry concerns pertaining to UDI.
  o Discussed the transition of the primary identifier for medical devices in the compendia files from the NDC or NHRIC to the UDI.
  o For July through September 2021, 2,899 new Structured Product Label (SPL) Billing Unit Index files were generated with one changed SPL Billing Unit Index file based on the files received by the FDA from the compendia. The compendia group has reconciled 20 of the 21 NDCs with discrepancies.
• The **Naming Standards for Drugs, Biologics and Biosimilars Task Group** reviewed issues resulting from the naming convention of biosimilar products and how these issues will affect provider, patient, payer and other issues concerning prior authorization for biosimilars. The task group:
  o Met with leaders of the Biosimilars Forum. Thayer Roberts presented to the task group about provider, patient, payer and other issues concerning prior authorization for biosimilars. The forum is a nonprofit that advocates for expanded access to and availability of biologics and is concerned about negative constraints on such access resulting from inconsistent and non-standardized prior authorization procedures affecting biosimilar product substitution.
  o Reviewed the listings for insulin glargine from FDA’s *Purple Book: List of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations* and identified the need for additional clarification from FDA staff.
  o Reviewed how the two Semglee® products are listed in the Purple Book, one with and one without a suffix. The task group is seeking clarification from Mylan on their plan and considering comment to FDA about the additional issues created by renaming an existing approved product.
  o Modified scope statement to address associated practice issues. The work group approved the modified scope statement.

• The **Outsourcing Facility Task Group** met to announce the FDA agreed with the request sent to an internal committee and a new SPL Marketing Category was created, Outsourcing Facility Compound Human Drug Product (Exempt from Approval Requirements) C181659.
  o Began discussions about the next steps to implement issues related to adding a new marketing category to existing databases throughout the members and stakeholders of NCPDP.

Other Reportables:

• **MC REMS Workflow to Transaction Task Group, MC NDC Scarcity Task Group** and **MC Digital Therapeutics Task Group**: Recaps for these task groups were provided in the WG2 download materials.

New Business:

• New QUIC Form Review and Final Adjudication:
  o QUIC #202103 QUIC Enzyvant Rethymic®
    BU = EA per section 5.1.7 of the BUS with a package quantity of 1 due to the variable strength, single-dose unit (72359-001-01).

**Work Group 7 Manufacturer and Associated Trading Partner Transaction Standards**

Ballot Adjudicated:

• **Ballot WG070014** Enhancements to the Manufacturer Rebate Standard Implementation Guide Version 07.04 is considered a valid ballot having received the required 60%+ of Consensus Group votes and 75%+ approval rating. No comments to the ballot were received. See Letter Ballot Comment spreadsheet for the ballot results on the WG7 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

DERFs/ECLs Reviewed:

• DERF 001861/ECL 000360 was recommended to MC to approve.
• DERF 001878/ECL 000364 was recommended to MC to approve.

Task Groups:
The Manufacturer Rebate Standard Task Group discussed challenges with rebills and ways to develop best practices.
The Medical Rebate Standard Task Group is on hiatus and did not meet this quarter.

Work Group 9 Government Programs

DERFs/ECLs Reviewed:
- DERF 001828 was approved as modified.
- DERF 001862/Emergency ECL 000361 was recommended to MC to approve as modified.
- DERF 001863 was approved.

Task Groups:
- The Government Programs Encounter Reporting Standard Task Group made modifications to the draft implementation guide and supporting documents for DERF 001828 to be presented at work group.
- The Hospice Task Group reviewed and edited Hospice Nx Processing Guidelines for Part D Plans to include definitions, processing guidelines, use case descriptions, consistency in verbiage and formatting. The task group also finalized the Hospice Nx Payer Sheet.
- The Prescription Drug Monitoring Programs Task Group made modifications to the PDMP Reporting Standard Implementation Guide and presented DERF 001863.
- The Prescription Drug Monitoring Programs Task Group – State PMP Tracking continued monitoring state PMP activity and updated the State PMP Tracking Document, which was approved by WG9.
- The Medicare Part D Frequently Asked Questions Task Group developed and presented DERF 001862/Emergency ECL 000361 to the work group based on the CY 2022 Part D Member Refusal Request Letter from CMS as well as an FAQ for the transition period until the reject codes requested in DERF 001862/Emergency ECL 000361 are published. The FAQ was approved as modified by WG9. The task group worked in conjunction with the WG1 Coordination of Benefits (COB) Task Group to develop an FAQ regarding Reject Code A5. The FAQ was approved as modified by WG9 for publication. The task group worked and will continue working with CMS on recommendations on streamlining Center for Program Integrity (CPI) electronic prior authorization (ePA) audits.
- The Medicaid Frequently Asked Questions Task Group discussed Medicaid provisions in the COVID relief package taking effect in 2022, including the requirement that state Medicaid plans cover patient costs incurred for items and services during patient participation in a clinical trial.
- The Coordination of Benefits Contractor (COBC)/Benefits Coordination and Recovery Center (BCRC) Task Group discussed Patient Assistance Program (PAP) deletions, worked with RelayHealth and Wisconsin SPAP to create a unique BIN/PCN for qualified plans versus non-qualified plans and continued to work with representatives from the BCRC to identify and resolve issues related to OHI records.
  - The Chapter 14 Review Sub-Task Group assigned Chapter 14 sections for review to other NCPDP task groups, developed rules for consistency in editing and began a thorough review process of the entire Chapter 14 document. The review target deadline is forecasted to be the end of 2021.
  - The Medicare Part D Section 111 Issues and Questions Sub-Task Group reviewed several User Guide updates to ensure an understanding and compliance by the Responsible Reporting Entities and collaborated with the Chapter 14 Review Sub-Task Group to review sections pertaining to Section 111.
• The **Medicare Financial Information Reporting (FIR) Task Group** made a request for a day-two trigger and met weekly to complete a review of Chapter 14 sections pertaining to FIR.

• The **Medicare Prescription Drug Event (PDE) Task Group** collaborated with the Chapter 14 Review Sub-Task Group to review sections of Chapter 14 pertaining to PDE. The task group submitted questions to and held a discussion with CMS regarding updates coming in 2022 to the Drug Data Processing System (DDPS).

• The **340B Task Group** did not meet this quarter.

• The **Medicare Standardized Fraud, Waste and Abuse Training Attestation Task Group** met to discuss attestation training available on the Medicare Learning Network (MLN) website.

**Work Group 10 Professional Pharmacy Services**

Task Groups:

• The **WG14/WG10 Standardized Medication Profile Task Group** did not meet this quarter.

• The **Identification of Social Determinants of Health Task Group** did not meet this quarter but plan to start meeting to resume working on the white paper.

• The **MTM and Pharmacist Clinical Services Task Group** decided to put the CMR Summary FHIR® wrapper project on hold until HL7® completes the **MCC eCare Plan** effort’s development of a FHIR® version of an eCare Plan Summary. The FHIR® eCare Plan Summary focused on engaging the patient in their care which mirrors the requirements for the CMR summary. For the Beneficiary Level Report (BLR), the task group continued to work on a guidance document recommending a BLR standard for exchange between the provider of the Medication Therapy Management (MTM) services to the Medicare Advantage Plan (MAPD) or prescription drug plan (PDP) including identification of NCPDP and/or HL7® standards.

• The **mL White Paper Task Group** did not meet this quarter. With the **NCPDP Recommendations for Standardizing Dosing in Metric Units (mL) on Prescription Container Labels of Oral Liquid Medications, Version 2.0** white paper published, the task group has met their goal and has decided to disband. WG10 voted to disband this task group.

• The **Universal Medication Schedule White Paper Task Group** did not meet this quarter. The task group continued to try to engage Mike Wolf, the principal investigator and advocate for UMS, in establishing strategies for revision of the white paper but has been unable to communicate with him. With the white paper published, the task group has met their goal and has decided to disband. WG10 voted to disband this task group.

• The **Pharmacogenomics Task Group** continued looking at various educational opportunities such as webinars and drafting a white paper. The task group continued to collaborate with other organizations to identify current processes and standards for pharmacogenomics and see where NCPDP can assist with the gaps.

Other Reportables:

• **WG18 Specialty Requirements for ePrescribing Task Group, WG14 Consultant Pharmacist Interoperability Task Group** and **WG1 Pharmacy Services Billing Task Group**: Recaps for these task groups were provided in the WG10 download materials.

Industry Updates:

• There was an update on the USP Compound Preparations Expert Panel.

**Work Group 11 ePrescribing & Related Transactions**

Ballot Adjudication:

Work Group Recap 6 of 12 November 2021
• **WG110087** Enhancements to the SCRIPT, Specialized and XML is considered a valid ballot having received the required 60%+ of Consensus Group votes and 75%+ approval rating. 37 affirmative comments and 2 accept with comments were received. WG11 reviewed and categorized one comment as Persuasive and Editorial and the remainder as Not Persuasive. See Letter Ballot Comment spreadsheet for the ballot results and comment adjudication on the WG11 webpage. The ballot will be sent to NCPDP Board of Trustees for approval after a 30-day appeal period.

**DERFs Reviewed:**
- DERF 001849 was denied.
- DERF 001864 was approved.
- DERF 001865 was approved.
- DERF 001866 was approved.
- DERF 001867 was approved as modified.
- DERF 001868 was approved.
- DERF 001869 was approved.
- DERF 001870 was approved.
- DERF 001871 was approved.
- DERF 001872 was pended.
- DERF 001873 was approved as modified.

**Task Groups:**
- The Dispensed Medication Reporting Task Group discussed an issue with the MedicationList layout. It was determined to be an error because the original DERF had the element of Quantity as optional. A correction was made to the schema and associated SCRIPT Implementation Guides since V2019071 and they have been republished.
- The ePrescribing Regulatory Task Group reviewed and submitted comments on the CMS-1751-P, Medicare Program, CY 2022 Payment Policies Under the Physician Fee Schedule and Other Changes to Part B Payment Policies, Medicare Shared Savings Program Requirements, Provider Enrollment Regulation Updates, Provider and Supplier Prepayment and Post-payment Medical Review Requirements.
- The Formulary and Benefit Task Group continued working on recommendations for the Formulary and Benefit Implementation Recommendations document for the NCPDP Formulary and Benefit Standard Version 53.
- The Implementation of Structured Sig Task Group brought forth DERFs 001849 and 001871.
- The Pharmacy to Pharmacy Prescription Transfer Task Group began working on new RxTransfer examples for the changes to the transactions to allow push or pull options for the transfer.
- The Prior Authorization Workflow to Transactions Task Group worked on topics including the inclusion of approval for denial letters in prior authorization (PA) response transactions and the expansion and clarity on the use of accurate ReasonCode values for closed PAInitiationResponse and PAResponse transactions.
- The WG11/WG14 RxFill Task Group brought forth DERFs 001865 and 001866.
- The SCRIPT Implementation Recommendations Task Group brought forth DERFs 001864 and 001873. They also received approval for several additions, modifications and deletions to the SCRIPT Implementation Recommendation document.
  - The RxChange Guidance Review Sub-Task Group brought forth DERF 001872.
- The XML Task Group continued to work in conjunction with the Implementation of Structured and Codified Sig Task Group to bring forth DERF 001871. The task group reviewed and provided recommendations on all submitted DERFs impacting the schema.
• The **WG14/WG11 LTPAC ePrescribing Task Group** brought forth DERFs 001867, 001868, 01869 and 001870. They also received approval for a new FAQ to be included in the *SCRIPT Implementation Recommendations* document.

**Other Reportables:**
- An Electronic Prescriptions for Controlled Substances (EPCS) update was provided.
- SCRIPT Version 2017071 NSC-II certified members were recognized.

**New Business:**
- The annual November review of changes to the NCPDP SCRIPT Standard was completed. The work group voted to request the NCPDP SCRIPT Standard V2022011 be named under MMA.

**WG14 Long Term and Post Acute Care (LTPAC)**

**Task Groups:**
- The **LTPAC Billing Issues Task Group** did not meet this quarter.
- The **Consultant Pharmacist Interoperability Task Group** worked on updating the current C-CDA guidance document, *Consultant Pharmacist Consult Note v1.0: Guidance on the Use of the HL7® CDA Consolidated Templates for Clinical Notes R2.1 Consult Note*, to incorporate FHIR® Resources.
- The **Long Term and Post-Acute Care ePrescribing Task Group** continued discussion about patient classification in jails to designate if a person is a state, country or federal inmate, reviewed proposed examples for benefits coordination and will continue working on the topic. The task group finalized the FAQ on pharmacy communication of previous RxReferenceNumber and current RxReferenceNumber upon renewal of prescription in the SCRIPT V2017071 standard. The task group also reviewed the following DERFs for modifications:
  - 001867
  - 001868
  - 001869
  - 001870
- The **WG14/WG10 Standardized Medication Profile Task Group** did not meet this quarter.
- The **WG11/WG14 RxFill Task Group** continued review and update of RxFill guidance in the *SCRIPT Implementation Recommendations* document. The task group reviewed DERFs 001865 and 001866 for modifications.
  - If no additional work is identified for the task group, the goal is to disband.

**Other Reportables:**
- Received a LTPAC industry update.

**Work Group 18 Specialty Pharmacy**

**Task Groups:**
- The **Specialty Requirements for ePrescribing Task Group** is encouraging all task group members to attend the **WG18 Patient Consent Task Group**. The task group will continue to work in sync with the Patient Consent Task Group.
- The **Specialty Pharmacy Data Exchange Task Group** continued working on the ‘Performance Metrics’ including structure, discussed possible beta implementation of the *Specialty Pharmacy Data Reporting Standard* (there is a pharmacy partner willing to pilot and need a manufacturer partner) and developed a survey to determine the need for a standard for performance metrics reporting.
• The **Benefit Coverage Identification Task Group** worked on a survey to identify time spent on benefit coverage verification. The task group created an introductory paragraph to explain purpose of the survey as well as drafted questions and defined variables for the survey. They completed a pilot of the survey and received 15 responses.

• The **Patient Consent Task Group** performed work toward supporting the task group’s two priority business cases within the NCPDP/HL7® Specialty Medication Enrollment FHIR® Implementation Guide (Unsolicited Consent and Consent Request/Response). The task group took steps to define consent additions to the existing *Specialty Medication Enrollment FHIR® Implementation Guide* and determined that it is feasible to meet the task group’s content and exchange flow goals through enhancement of the *Specialty Medication Enrollment FHIR® Implementation Guide*.

• The **Facilitating Access to Specialty Products Task Group** developed a recommendations paper providing information to manufacturers, prescribers, payers and pharmacies regarding hub services and limited distribution products. The task group received additional feedback from the Standardization Committee. The task group has been meeting to address these revisions and has made updates to the visuals based on feedback from the NCPDP marketing team.

**Other Reportables:**

• **WG10 Identification of Social Determinants of Health Task Group**, **WG11 Prior Authorization Workflow-to-Transaction Task Group**, **MC REMS Workflow-to-Transaction Task Group** and **MC Real Time Prescription Benefit Standard Task Group**: Recaps for these task groups were provided in the WG18 download materials.

**New Business:**

• Promoted the upcoming Virtual Educational Summit.
• Promoted the upcoming Specialty Pharmacy webinar.

**Work Group 45 External Standards Assessment and Implementation Guidance**

DERFs/ECLs Reviewed:

• DERF 001874 was approved as modified.
• DERF 001875/ECL 000362 was recommended to MC to approve.

**Old Business:**

• Industry updates were provided for WEDI, NCPDP SNIP, CAQH CORE and X12.

**Task Groups:**

• The **Pharmacy and/or Combination ID Card Task Group** presented an updated version of the Pharmacy and/or Combination ID Implementation Guide for publication and has requested new code values be added to the Health Care ID Card Qualifier (A35) to accommodate the information required on ID cards based on the Consolidated Appropriations Act of 2021.

• The **834/835 FAQ Task Group** did not meet this quarter, but they are looking for a new task group lead.

• The **Document Revisions Task Group** did not meet this quarter.

• The **DSMO Task Group** received no DSMO requests for review.

**MC Maintenance and Control – DERF Harmonization**

**New Business:**

• Pended DERF 001835 was previously referred to Work Group 9 Government Programs for review for harmonization.
• DERF 001857/ECL 000357 was referred to Work Group 11 ePrescribing & Related Transactions for review for harmonization.
• The following DERFs were highlighted to create awareness:
  o DERF 001828
  o DERF 001854
  o DERF 001858/ECL 000358
  o DERF 001862/Emergency ECL 000361
  o DERF 001863
  o DERF 001865
  o DERF 001866
  o DERF 001867
  o DERF 001868
  o DERF 001869
  o DERF 001870

MC Maintenance and Control
DERFs/ECLs: 25 new and 3 pended DERFs/ECLs were reviewed (see WG1, WG2, WG7, WG9, WG11 and WG45).
• DERF 001828 was approved as modified.
• DERF 001835 was approved as modified.
• DERF 001849 was denied.
• DERF 001854 was approved.
• DERF 001855/ECL 000355 was approved.
• DERF 001856/ECL 000356 was approved as modified.
• DERF 001857/ECL 000357 was approved.
• DERF 001858/ECL 000358 was approved as modified.
• DERF 001859/ECL 000359 was approved as modified.
• DERF 001860 was approved.
• DERF 001861/ECL 000360 was approved.
• DERF 001862/Emergency ECL 000361 was approved as modified.
• DERF 001863 was approved.
• DERF 001864 was approved.
• DERF 001865 was approved.
• DERF 001866 was approved.
• DERF 001867 was approved as modified.
• DERF 001868 was approved as modified.
• DERF 001869 was approved.
• DERF 001870 was approved.
• DERF 001871 was approved.
• DERF 001872 was pended.
• DERF 001873 was approved as modified.
• DERF 001874 was approved as modified.
• DERF 001875/ECL 000362 was approved.
• DERF 001876 was approved.
• DERF 001877/ECL 000363 was approved.
• DERF 001878/ECL 000364 was approved.
Old Business:
- Received updates from:
  - Board of Trustees
  - SNIP Committee
- Updates for the following were provided in the MC download materials:
  - HIPAA
  - DSMO Change Request System (CRS) Requests No. 1201, 1202 and 1208

Task Groups:
- The **Education/Legislation and Regulations Task Group** submitted comments to the Office of the National Coordinator for Health Information Technology (ONC) regarding the 2021 ONC Interoperability Standards Advisory (ISA) Document.
- The **Emergency Preparedness Task Group** updated the *NCPDP Emergency Preparedness Guidance Document* to incorporate FAQs for guidance on boosters and additional doses and for billing for OTC products such as home testing kits. The work group approved the updated document.
- The **X12 TR3 Comment Consolidation Task Group** is on hiatus and did not meet this quarter.
- The **Real Time Prescription Benefit Standard (RTPB) Task Group** reviewed examples of messages in the Message (504-F4) field. DERF 001876 was submitted to create a message field at the coverage status level. The task group also began to identify new data elements and ECL values to codify information currently being communicated in the Message (504-F4) field. A sub-task group, **Related RTPB Law Review**, was created to review state legislative activity related to real-time benefit tools for providers.
  - The **Consumer-Facing RTPB and Price Transparency Sub-Task Group** decided to support the HL7® FHIR® CARIN Consumer Real Time Pharmacy Benefit Check as the solution for consumer RTPB. The sub-task group consequently revised their name to be the Consumer and Provider RTPB Standards Monitoring Sub-Task Group and changed their scope to focus on monitoring modifications of both the NCPDP provider and the HL7® consumer RTPB standards. They also began reviewing the changes to the NCPDP RTPB Standard from Beta version to Version 12 for applicability to the consumer RTPB.
  - The **Related RTPB Law Review Sub-Task Group** was created in September 2021 to review 2021 state legislative activity related to requirements for provider real-time prescription benefit tools. The sub-task group has begun to review passed and proposed legislation to identify any potential gaps in the RTPB Standard.
- The **Gender Transition Task Group** decided to go on hiatus.
- The **Digital Therapeutics Task Group** drafted a survey to solicit feedback from the digital therapeutics industry to help determine subsequent use cases to be addressed by the task group. The task group also completed a review of the Manufacturer Rebate and Medical Rebate Data Submission Standards for a gap analysis.
- The **NDC Scarcity Task Group** is on hiatus and did not meet this quarter. The task group will resume meeting to address the issue of expanded product service identifier implementation in time to accommodate the Telecommunication Standard Version F6 implementation.
- The **Patient Identification Task Group** did not meet this quarter. The updated *Universal Patient Identifier Guidance Document Version 1.2* was published. The task group requested to disband and MC voted to approve the request.
- The **Definition and Use of Quantity and Day Supply Task Group** completed edits to a pended Version D.0 Editorial Guide FAQ about Days Supply (405-D5) estimation. The task group also completed a FAQ for Days Supply (405-D5) representation.
• The **REMS Workflow to Transactions Task Group** continued working with the REMS functionality matrix to identify processes/transactions that create inefficiencies. The task group is also in the process of identifying NCPDP transactions to help standardize and expedite REMS processes.

• The **NCPDP Standards Message Structure Harmonization Task Group** developed a survey to get input as to which standards may need to move or would benefit from moving to a different format.

New Business:

• New Project Development Form 000056 Reconciled Medication List was discussed with many questions raised about the actions that should be undertaken by NCPDP. The PDF was pended to the WG14/WG10 Standardized Medication Profile Task Group to work with the submitter to bring the form back for the February 2022 Work Group.

• Received an update on NCPDP Foundation projects.